Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Industry's Drug Pricing System Reform Proposals Incompatible with Current System: Mr Tsushima
September 3, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Korosho to Create Council for Promotion of Generics in Each Prefecture
September 3, 2007
-
ARCHIVE JMA to Survey Medical Professionals' Views on Quality of Generics
September 3, 2007
-
COMMENTARY COMENTARY:Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
-
ARCHIVE Discussions Start for Revision of Ethical GL for Clinical Research
September 3, 2007
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
September 3, 2007
-
ARCHIVE R&D NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Daiichi Sankyo Ties Up with Forest Lab. for AZOR
September 3, 2007
-
ARCHIVE Japan Tissue Engineering's Autologous Epidermis Recommended for Approval
September 3, 2007
-
ARCHIVE Teijin to Codevelop Ipsen's ITM-077 with Chugai
September 3, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Peptisyntha to Expand Contract Peptide Manufacturing Business in Japan
September 3, 2007
-
ARCHIVE Drugs Account for 21.7% of Medial Expenditure
September 3, 2007
-
ARCHIVE DSP to Increase Its MRs' Scientific Knowledge
September 3, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 3, 2007
-
COMMENTARY COMMENTARY/NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
-
ARCHIVE Vice Health Minister Unofficially Meets JGPMA Leaders to Promote Use of Generics
August 27, 2007
-
ARCHIVE Antidepressant Medication Altered by 40% of Patients: GSK
August 27, 2007
-
ARCHIVE 47 Programs in PII Trials: Pfizer
August 27, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…